- Regular updates
- No spam
You are here
Spin-off launched in protein bio-markers
The company will develop and market a new generation of molecular diagnostics − so-called protein bio-markers − using innovative proteomics technology developed by a research group under the direction of Joël Vandekerckhove.
The markers can be used in the development of medicines, making the process much more efficient, effective and economical. They will also enable doctors to detect diseases sooner and, because many medicines work effectively only with a limited group of patients, doctors will also be able to verify whether a particular medicine will work for certain individuals.
Peakadilly will be led by Koen Kas, who has been closely involved in the development of the technology platform.